Advertisement

Topics

Protalex Company Profile

08:54 EST 13th December 2018 | BioPortfolio

Protalex (OTC:PRTX) is a biotechnology company developing a novel, new class of drugs for the treatment of various autoimmune disorders. The company’s lead compound, PRTX-100, is currently in development for idiopathic thrombocytopenic purpura, a rare blood clotting disorder, and rheumatoid arthritis. PRTX-100, a highly-purified form of Staphylococcal Protein A (SpA or Protein A) has been used in FDA-approved extracorporeal immunoadsorption systems for both idiopathic thrombocytopenic purpura and rheumatoid arthritis. Protalex believes that direct administration of PRTX-100 via I.V. bolus will prove a much more effective therapy for these and other indications. Protalex is building a strong proprietary position with multiple patents pending; chief among them is the “Protein A Compositions and Methods of Use” patent which was filed with the U.S. Patent and Trademark Office in April 2002. This broad use patent protects the company’s lead compound PRTX-100 for treatment of a variety of autoimmune diseases in addition to idiopathic thrombocytopenic purpura and rheumatoid arthritis, providing a significant barrier to entry for others. The Company has also filed for foreign protection relating to this patent in Canada, Japan and the European Union. Additionally, patent applications relating to the manufacturing process of PRTX-100 and new compounds are currently in process. Protalex is headquartered in New Hope, Pennsylvania. The Company currently has 10 full-time employees engaged in R&D, clinical research, management and administrative functions.

Location

145 Union Square Drive
New Hope
Pennsylvania
18938
United States of America

Contact

Phone: 215-862-9720
Email: info@protalex.com


News Articles [5 Associated News Articles listed on BioPortfolio]

Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis

Findings Support Advancement of PRTX-100 into its Third Clinical Indication Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced pre...

Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Immune Thrombocytopenia Presented at the European Hematology Association 23rd Annual Meeting

Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that data highlighting results from its European Phase 1b open-label, dose-escalation stu...

Protalex Inc PRTX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryProtalex Inc Protalex is a biopharmaceutical company that develops drugs for the treatment of autoimmune and inflammatory diseases. The company offers treatment for a range of autoimmune diseas...

Protalex Inc PRTX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09052018] Prices from USD $250

SummaryProtalex Inc Protalex is a biopharmaceutical company that develops drugs for the treatment of autoimmune and inflammatory diseases. The company provides treatment for a range of autoimmune dise...

Protalex Inc PRTX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250

SummaryProtalex Inc Protalex is a biopharmaceutical company that develops drugs for the treatment of autoimmune and inflammatory diseases. The company provides treatment for a range of autoimmune dise...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but...

Protalex

Protalex (OTC:PRTX) is a biotechnology company developing a novel, new class of drugs for the treatment of various autoimmune disorders. The company’s lead compound, PRTX-100, is currently in devel...

More Information about "Protalex" on BioPortfolio

We have published hundreds of Protalex news stories on BioPortfolio along with dozens of Protalex Clinical Trials and PubMed Articles about Protalex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Protalex Companies in our database. You can also find out about relevant Protalex Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...


Corporate Database Quicklinks



Searches Linking to this Company Record